Short Interest in Allakos Inc. (NASDAQ:ALLK) Decreases By 14.3%

Allakos Inc. (NASDAQ:ALLK) was the target of a large decline in short interest in the month of October. As of October 30th, there was short interest totalling 5,160,000 shares, a decline of 14.3% from the October 15th total of 6,020,000 shares. Currently, 19.1% of the shares of the company are short sold. Based on an average daily trading volume, of 211,800 shares, the short-interest ratio is presently 24.4 days.

ALLK has been the subject of several research analyst reports. Lifesci Capital reaffirmed an “outperform” rating on shares of Allakos in a report on Thursday, October 22nd. BidaskClub raised shares of Allakos from a “buy” rating to a “strong-buy” rating in a report on Friday, November 6th. Finally, Zacks Investment Research downgraded shares of Allakos from a “hold” rating to a “sell” rating in a report on Thursday, November 5th. Two research analysts have rated the stock with a sell rating, two have given a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $67.67.

NASDAQ ALLK opened at $101.41 on Friday. The company has a market capitalization of $5.32 billion, a P/E ratio of -37.01 and a beta of 1.01. Allakos has a 12-month low of $41.60 and a 12-month high of $139.99. The firm has a 50-day moving average price of $90.18 and a two-hundred day moving average price of $80.20.

Allakos (NASDAQ:ALLK) last posted its quarterly earnings data on Saturday, November 14th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.82) by ($0.04). As a group, research analysts forecast that Allakos will post -3.07 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Prospera Financial Services Inc bought a new stake in Allakos in the 3rd quarter valued at about $38,000. Strs Ohio bought a new stake in shares of Allakos during the 2nd quarter worth approximately $35,000. Meeder Asset Management Inc. bought a new stake in shares of Allakos during the 3rd quarter worth approximately $60,000. Nisa Investment Advisors LLC lifted its holdings in shares of Allakos by 17.4% during the 3rd quarter. Nisa Investment Advisors LLC now owns 885 shares of the company’s stock worth $72,000 after acquiring an additional 131 shares during the period. Finally, Smith Asset Management Group LP lifted its holdings in shares of Allakos by 47.7% during the 3rd quarter. Smith Asset Management Group LP now owns 960 shares of the company’s stock worth $78,000 after acquiring an additional 310 shares during the period. 64.16% of the stock is owned by hedge funds and other institutional investors.

About Allakos

Allakos Inc operates as a clinical stage biopharmaceutical company. The company is developing antolimab (AK002) for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Allakos Inc was founded in 2012 and is headquartered in Redwood City, California.

Featured Story: Trading signals using Bollinger bands

Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.